Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist studied for glycemic control, weight management, and metabolic health in research models.
Molecular Structure
Amino Acid Sequence
Molecular Formula
Molecular Weight
Half-Life
CAS Number
What is Tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide engineered to activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It is the first such dual incretin agonist developed and approved for clinical use. Developed by Eli Lilly, the peptide structure is based on the native GIP sequence with modifications that confer GLP-1 receptor agonism, plus a C20 fatty diacid moiety attached at lysine position 20 to enable reversible albumin binding and extend half-life.
Tirzepatide is notable in research for the magnitude of metabolic effects observed in trials and for the scientific interest generated by its dual-incretin mechanism. The SURPASS clinical trial program in type 2 diabetes and the SURMOUNT program in obesity have produced substantial published evidence, with head-to-head trials demonstrating greater HbA1c reductions and greater weight loss than selective GLP-1 agonists. Active investigation continues into effects on heart failure, NASH, sleep apnea, and kidney outcomes.
Mechanism of action
Tirzepatide’s mechanisms of action have been investigated across multiple pathways:
- GLP-1 receptor agonism: The peptide stimulates glucose-dependent insulin secretion, suppresses inappropriate glucagon release, delays gastric emptying, and acts on central appetite-regulating circuits in the hypothalamus and brainstem.
- GIP receptor agonism: Activation of the GIP receptor enhances insulin secretion synergistically with GLP-1 and modulates adipose tissue function, with research suggesting effects on lipid metabolism and energy expenditure.
- Glucose-dependent insulinotropic effects: Both incretin pathways converge to produce robust glucose-dependent insulin release from pancreatic beta cells while reducing the risk of hypoglycemia.
- Central appetite regulation: Studies have documented effects on hypothalamic arcuate nucleus and brainstem signaling, contributing to reductions in food intake and changes in food preference.
- Albumin-mediated half-life extension: The C20 fatty diacid sidechain enables reversible albumin binding, dramatically extending plasma residence time and supporting once-weekly dosing.
- Effects on hepatic and adipose tissue: Research has documented improvements in hepatic fat content and adipose tissue function beyond what is achieved with selective GLP-1 agonism.
These pathways are characterized in both preclinical models and human clinical research.
Research applications
Tirzepatide has been investigated across several research domains, with the most active areas including:
- Type 2 diabetes (SURPASS program): Multiple Phase 3 trials evaluated tirzepatide across diverse populations. SURPASS-2, a head-to-head trial against semaglutide, demonstrated superior HbA1c reduction and greater weight loss with tirzepatide at comparable doses.
- Obesity (SURMOUNT program): SURMOUNT-1 documented mean weight reductions of approximately 20.9% at the highest dose over 72 weeks in participants without diabetes, among the largest weight reductions observed with a non-surgical intervention.
- Cardiovascular and metabolic research: The SURPASS-CVOT cardiovascular outcomes trial is ongoing. Sub-studies have examined effects on non-alcoholic steatohepatitis with significant improvements in liver histology, and SURMOUNT-OSA examined obstructive sleep apnea outcomes.
- Heart failure research: The SUMMIT trial examined effects in heart failure with preserved ejection fraction, an emerging area for incretin-based therapies.
- Body composition and lipid research: Studies have documented improvements in lipid profiles, hepatic fat content, and cardiometabolic markers exceeding those observed with selective GLP-1 agonists.
This compound is intended for laboratory research use only. It has not been approved for human therapeutic use by any regulatory agency.
Storage & reconstitution
In its lyophilized form, tirzepatide tolerates ambient temperatures during shipping but should be stored long-term at -20°C, protected from light. Properly stored lyophilized peptide remains stable for 24 months or longer.
Once reconstituted with bacteriostatic water for injection, tirzepatide solutions should be stored refrigerated at 2-8°C and used within 28 days. Avoid repeated freeze-thaw cycles, which can degrade peptide structure and reduce activity.
Visual inspection should be performed before each use. The reconstituted solution should be clear and colorless. Reject any solution that appears cloudy, discolored, or contains visible particulate matter.
For step-by-step reconstitution calculations, see our reconstitution calculator.
For laboratory research use only. The compound described on this page is intended exclusively for in vitro research and laboratory experimentation by qualified researchers and is not for human or veterinary use. It is not a drug, food, dietary supplement, or cosmetic, and has not been approved by the FDA, Health Canada, EMA, or any other regulatory authority for the diagnosis, treatment, cure, mitigation, or prevention of any disease or medical condition. The information provided on this page is for educational and reference purposes only and does not constitute medical advice. By accessing this content you confirm that you are a qualified researcher purchasing for legitimate laboratory purposes.